Singapore still falling short for home-grown biotechs seeking IPO
Tough SGX mainboard listing rules, low liquidity, lack of deep institutional investor pool and sparse research ecosystem among reasons cited
Singapore
HOME-GROWN biotech companies would rather look for opportunities further ashore than list on the Singapore Exchange (SGX). Although the city-state has a growing biotech ecosystem, the local bourse has not been able to benefit much from it.
Industry players who spoke to The Business Times brought up issues of low liquidity, the lack of a deep institutional investor pool and a sparse research ecosystem as reasons why they would look elsewhere.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Startups
Semiconductor unicorn Silicon Box vows to avoid geopolitical mire
A cheat sheet of startup and tech M&As in South-east Asia
Zilingo ex-CEO’s criminal complaint is retaliation against whistleblowers: source
Gojek and ComfortDelGro Taxi to send untaken rides to each other’s platforms
SG fintech firm Bambu shuts down after missing profit targets, says founder
Telemedicine platforms evolve beyond virtual consultations